Mechanisms of Adstiladrin Sensitivity and Resistance in Bladder Cancer
Abstract
Adstiladrin (nadofaragene firadenovec) is an adenoviral gene therapy construct that was developed for the local treatment of patients with high-risk non-muscle invasive bladder cancer. The overall goal of the work that is being performed at Johns Hopkins is to perform tissue- and urine-based genomic studies on the samples collected within the context of the Phase III trial to identify biomarkers that predict response and/or resistance. Emerging evidence indicates that urine tumor DNA measurements can be used to distinguish the effects of surgery (TURBT) versus intravesical BCG. Therefore, using separate sources of funding and in collaboration with Convergent Genomics, we performed pilot retrospective studies on urine collected in the Phase II trial to determine whether urine tumor DNA characteristics correlated with recurrence-free survival. This work was successful, setting the stage for validation (pending DOD approval of a revised SOW) with the samples from the Phase III trial.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 11, 2024
- Accession Number
- AD1223421
Entities
People
- David J. Mcconkey
- Woonyoung Choi
- Yujiro Hayashi
Organizations
- Johns Hopkins University